Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
0.502 USD | +0.40% |
|
+2.74% | -64.65% |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Strengths
- Its core activity has a significant growth potential and sales are expected to surge, according to Standard & Poor's' forecast. Indeed, those may increase by -100% by 2026.
- The company shows low valuation levels, with an enterprise value at 0.07 times its sales.
- The company has a low valuation given the cash flows generated by its activity.
- Over the last twelve months, the sales forecast has been frequently revised upwards.
- Growth remains a strong point in this company. In their sales forecast, analysts sound optimistic with regard to sales prospects.
- For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Weaknesses
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- Low profitability weakens the company.
- For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
- The average consensus view of analysts covering the stock has deteriorated over the past four months.
- Over the past twelve months, analysts' consensus has been significantly revised downwards.
- Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
- Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
Ratings chart - Surperformance
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-64.65% | 80.61M | - | ||
+17.14% | 44.63B | B- | ||
+42.66% | 40.46B | A | ||
-8.10% | 38.07B | B | ||
+33.22% | 32.27B | B | ||
-7.10% | 27.3B | C | ||
+14.52% | 26.53B | B- | ||
+48.29% | 14.06B | B+ | ||
+32.96% | 12.54B | C+ | ||
-7.84% | 11.28B | B+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
- Stock Market
- Equities
- PIII Stock
- Ratings P3 Health Partners Inc.